Economic Observation Network Sinovac Biotech (SVA) reported a net loss of $60.2 million to its parent company in the first half of the year, which expanded year-on-year. The gross profit margin increased, but research and development expenses decreased.

Performance and business situation:
In the first half of the year, the net loss attributable to the parent company was 60.2 million US dollars, far exceeding the same period last year (21.66 million US dollars) But upon closer inspection, the expansion of losses is mainly due to the "minority shareholder subsidiaries" bearing more expenses (increased general administrative expenses, decreased investment returns), rather than the deterioration of core business. Gross profit margin increased from 62.5% to 65.0% This indicates that the profitability of selling goods is actually improving. Don't be intimidated by surface numbers, but also be aware that research and development expenses have significantly decreased year-on-year ($83.2 million vs $127 million). If there is a sustained reduction, the long-term pipeline competitiveness will be discounted 。

The above content is based on publicly available information and does not constitute investment advice.